China's Biotech Industry

Deals reached a record high of $110 billion in H12026.

• As of June 30, China's ⁠innovative drugs have been out-licensed to foreign companies in 81 deals.
• A licensing agreement grants a company the rights to develop, manufacture or commercialise another company's pharmaceutical products or technologies in exchange for an upfront fee ‌or ⁠future target-based payments, mitigating development risks.
• The deal value has already reached 80% of 2025's full-year total.
• The products licensed covered ⁠therapeutic areas including oncology, metabolism, immunology, and neurology.
• The main licensee companies came from countries ⁠including the U.S., Britain, France and Italy.
• Global drugmakers are
  Please, Log in or Register to view URLs content!
  for China-developed experimental medicines ahead of
  Please, Log in or Register to view URLs content!
  .

Click to expand...

In the first half of 2026, China's output and licensing deals in the biotech industry almost doubled those in 2025.

supercat said:

In the first half of 2026, China's output and licensing deals in the biotech industry almost doubled those in 2025.

https://twitter.com/i/web/status/207650311740401696026

Please, Log in or Register to view URLs content!

Click to expand...

curious, incase of production, will the factories be located in China? does it include in their deals?

The world's first bionic auditory neural interface helps patients not only hear sound/speech, but also helps patient understand it:

Spinal cord injury is difficult to treat. Chinese researchers have developed a programmable, controlled-release bionic spinal cord graft that gives patients new hope.

Programmable Controlled-Release Bionic Spinal Cord Graft Promotes Repair and Functional Recovery after Spinal Cord Injury​

Click to expand...

China's first "second-level rotation speed coaxial coplanar diagnostic CT-guided medical linear accelerator" has successfully entered the special review procedure​

According to CNNC (China National Nuclear Corporation), the “second-level rotation speed coaxial coplanar diagnostic CT-guided medical linear accelerator” independently developed by CNNC Particle Technology has recently successfully entered the special review procedure for national innovative medical devices at the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration .



as the first domestically produced medical electronic linear accelerator with second-level rotation speed and coaxial coplanar diagnostic CT to enter the approval process, this product achieves an integrated design of electronic linear accelerator and fan-beam CT on the same gantry and in the same plane. It can complete the acquisition of diagnostic-grade CT images and precise positioning guidance simultaneously in the treatment position. Relying on high-definition airborne imaging and intelligent operating system, it also realizes the optimization of the entire process from precise positioning to efficient treatment.

China's BCI is not as invasive as Neuralink's.

While Musk’s Neuralink drills into skulls, China’s BrainCo bets the future of brain tech is wearable​

• Companies around the world, especially in the U.S. and China, are racing to build brain-computer interfaces – some through invasive implants, others by skipping surgery altogether.
• Investors and industry players say the market for “augmenting” human abilities beyond therapeutic uses, remains many years away.
• China is pushing to develop neurotechnology, from national policy to hospital partnerships to commercialization. CNBC goes inside a Hangzhou-based startup at the center of that push.

Click to expand...

Extracting just 1 gram from 2 tons: Zhejiang University overcomes synthesis bottleneck for the exorbitantly expensive anti-cancer drug vinblastine, boosting yield nearly 1,000-fold.

China's first national BCI prescription went through and surgery completed for hand motor functionality.